The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of ABX196 in combination with nivolumab in patients with previously treated hepatocellular carcinoma (HCC).
 
Darren Sigal
Stock and Other Ownership Interests - Celularity; Cend Therapeutics; Karyopharm Therapeutics; Novartis
Honoraria - Ipsen
Consulting or Advisory Role - Celularity; Cend Therapeutics
Speakers' Bureau - Ipsen
Research Funding - Abivax; ARIAD/Incyte; OBI Pharma
Patents, Royalties, Other Intellectual Property - Patent on "a method for treating neuroendocrine tumors" using TRK inhibitors.
 
Munveer Singh Bhangoo
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
 
Catherine T. Frenette
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Merck
Speakers' Bureau - Abbvie; Bayer; Bristol meyers squibb; Eisai; Exelixis; Genentech; Gilead Sciences; Intercept Pharmaceuticals; Salix
Research Funding - Bayer (Inst); Exelixis (Inst); GENFIT (Inst); Merck (Inst)
 
Sunyoung S. Lee
Research Funding - Merck KGaA (Inst)
 
Christine Fark
No Relationships to Disclose
 
Paul Gineste
No Relationships to Disclose
 
Anais Vissian
Employment - ABIVAX
Stock and Other Ownership Interests - ABIVAX (I)
 
Luc Teyton
Stock and Other Ownership Interests - Abivax
Consulting or Advisory Role - Abivax
 
Tillman E. Pearce
Employment - Abivax; OBI Pharma
Leadership - CureBiotech; OBI Pharma
Stock and Other Ownership Interests - OBI Pharma
Travel, Accommodations, Expenses - OBI Pharma
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck